Search results
Who we are. As a leading global clinical-stage biopharmaceutical company, we strive to create transformative medicines to protect and improve people’s lives. Fueled by our proprietary RNA technology platform combined with two decades of science and manufacturing excellence, we are dedicated to creating novel treatments that enable the body to ...
- Pipeline
CureVac aims to leverage its unique technology to provide...
- About Us
Officially founded in 2000, CureVac is the world’s first...
- Overview
The Annual General Meeting (the “AGM”) of Shareholders of...
- Technology
Each CureVac product can be thought of as a tailored...
- News
CureVac Advances Seasonal Flu Study to Phase 2 in...
- Career
CureVac is commited to equal employment opportunity and...
- Production
CureVac is truly a one-stop shop for mRNA therapeutics,...
- Publications
CureVac has been on the record as a pioneer in the mRNA...
- Pipeline
Aug 1, 2023 · CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in ...
www .curevac .com. Headquarters of CureVac in Tübingen. CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee.
Aug 18, 2022 · EN. Press Release. August 18, 2022. CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate. Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines.
Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies. All candidates use CureVac’s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses.
